[go: up one dir, main page]

NO912071L - Fremgangsmaater for fremstilling av anti-tumorforbindelser - Google Patents

Fremgangsmaater for fremstilling av anti-tumorforbindelser

Info

Publication number
NO912071L
NO912071L NO91912071A NO912071A NO912071L NO 912071 L NO912071 L NO 912071L NO 91912071 A NO91912071 A NO 91912071A NO 912071 A NO912071 A NO 912071A NO 912071 L NO912071 L NO 912071L
Authority
NO
Norway
Prior art keywords
alkyl
carbon atoms
hydrogen
pharmaceutically acceptable
formula
Prior art date
Application number
NO91912071A
Other languages
English (en)
Other versions
NO912071D0 (no
Inventor
Robert George Andrew
Andrew John Barker
Francis Thomas Boyle
James Michael Wardleworth
Original Assignee
Ici Plc
Nat Res Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10676728&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO912071(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ici Plc, Nat Res Dev filed Critical Ici Plc
Publication of NO912071D0 publication Critical patent/NO912071D0/no
Publication of NO912071L publication Critical patent/NO912071L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Oppfinnelsen angår fremgangsmåter for fremstilling av. kinazolinderivater, eller farmasøytisk akseptable salter derav, som har anti-tumoraktivitet. Forbindelsene kan inngå i farmasøytiske preparater.Kinazolinderivatene har formelen:. hvorinnbefatter hydrogen, amino og alkyl eller alkoksy hver med opp til 4 karbonatomer;. Rinnbefatter hydrogen, alkyl, hydroksyalkyl og halogenalkyl hver med opp til 4 karbonatomer;. Rer hydrogen eller alkyl med opp til 3 karbonatomer;. Ar er fenylen eller heterocyklen;. L er en gruppe med formel -CO.NH-, -NH.CO-, -O.NR'-, -NR'.-,. -CH=- eller -CO.O-, hvor R' er alkyl med opp til 4 karbonatomer; og. Y er en nærmere beskrevet forgrenet alkylgruppe som har substituentene Yog Ysom, uavhengig av hverandre, innbefatter hydroksy, cyano, aryl og heteroaryl, og hvor definisjonen av Yeventuelt også innbefatter sulfo, N-fenylsulfonylkarbamoyl og 5-tetrazolyl;. eller et farmasøytisk akseptabelt salt derav.
NO91912071A 1990-05-30 1991-05-29 Fremgangsmaater for fremstilling av anti-tumorforbindelser NO912071L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9011989 1990-05-30

Publications (2)

Publication Number Publication Date
NO912071D0 NO912071D0 (no) 1991-05-29
NO912071L true NO912071L (no) 1991-12-02

Family

ID=10676728

Family Applications (1)

Application Number Title Priority Date Filing Date
NO91912071A NO912071L (no) 1990-05-30 1991-05-29 Fremgangsmaater for fremstilling av anti-tumorforbindelser

Country Status (15)

Country Link
US (1) US5280027A (no)
EP (1) EP0459730A3 (no)
JP (1) JPH04235173A (no)
AU (1) AU640016B2 (no)
CA (1) CA2042922A1 (no)
CS (1) CS160591A3 (no)
FI (1) FI912600A (no)
GB (1) GB2244708B (no)
HU (1) HUT57739A (no)
IE (1) IE64085B1 (no)
IL (1) IL98167A0 (no)
NO (1) NO912071L (no)
NZ (1) NZ238259A (no)
PT (1) PT97799A (no)
ZA (1) ZA913730B (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105771D0 (en) * 1991-03-19 1991-05-01 Cancer Res Inst Royal Anti-cancer compounds
GB9205320D0 (en) * 1992-03-11 1992-04-22 Ici Plc Anti-tumour compounds
GB9205907D0 (en) * 1992-03-18 1992-04-29 Cancer Res Inst Royal Anti-cancer compounds
US5430148A (en) * 1992-03-31 1995-07-04 Agouron Pharmaceuticals, Inc. Antiproliferative quinazolines
GB9220571D0 (en) * 1992-09-30 1992-11-11 Ici Plc Quinazoline derivatives
CA2230082C (en) 1995-08-22 2005-07-05 Japan Tobacco Inc. Amide compounds and use thereof
ATE212632T1 (de) * 1995-09-08 2002-02-15 Univ Princeton Nicht-klassische antifolate
GB9904275D0 (en) * 1999-02-24 1999-04-21 Cancer Res Campaign Tech Anti-cancer compounds
US6518292B1 (en) * 1999-03-12 2003-02-11 Bristol-Myers Squibb Co. Heterocyclic aromatic compounds usefuls as growth hormone secretagogues
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US7230000B1 (en) * 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
US6753428B2 (en) * 2001-11-20 2004-06-22 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
JP2005529076A (ja) * 2002-02-15 2005-09-29 サイトキネティクス・インコーポレーテッド キナゾリノンの合成
US7214800B2 (en) 2002-05-09 2007-05-08 Cytokinetics, Inc. Compounds, compositions, and methods
MXPA04011074A (es) * 2002-05-09 2005-06-08 Cytokinetics Inc Compuestos de pirimidinona, composiciones y metodos.
US7038048B2 (en) * 2002-05-23 2006-05-02 Cytokinetics, Inc. 3H-pyridopyrimidin-4-one compounds, compositions, and methods of their use
CA2489367A1 (en) * 2002-06-14 2003-12-24 Cytokinetics, Inc. Compounds, compositions, and methods
AU2003256805A1 (en) * 2002-07-23 2004-02-09 Cytokinetics, Inc. Compounds compositions and methods
WO2004018058A2 (en) * 2002-08-21 2004-03-04 Cytokinetics, Inc. Compounds, compositions, and methods
AU2003277079A1 (en) 2002-09-30 2004-05-04 Cytokinetics, Inc. Compounds, compositions, and methods
US20050197327A1 (en) * 2003-11-03 2005-09-08 Gustave Bergnes Compounds, compositions, and methods
JP2007510660A (ja) * 2003-11-07 2007-04-26 サイトキネティクス・インコーポレーテッド 化合物、組成物及び方法
JP2007513154A (ja) * 2003-12-08 2007-05-24 サイトキネティクス・インコーポレーテッド 化合物、組成物及び方法
CN101801937A (zh) * 2007-06-22 2010-08-11 艾科尔公司 喹唑啉酮化合物及其使用方法
DE102010001064A1 (de) * 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
JP2014527511A (ja) 2011-06-24 2014-10-16 アムジエン・インコーポレーテツド Ｔｒｐｍ８拮抗剤及び治療におけるそれらの使用
JP2014517074A (ja) 2011-06-24 2014-07-17 アムジエン・インコーポレーテツド Ｔｒｐｍ８アンタゴニストおよび治療におけるそれらの使用
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
US10413583B2 (en) * 2016-11-30 2019-09-17 The University Of Chicago Synthetic substrates for enzymes that catalyze reactions of modified cysteines and related methods
US20250026763A1 (en) * 2023-05-25 2025-01-23 Allorion Therapeutics Inc Egfr inhibitors and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0031237B1 (en) * 1979-12-19 1984-10-17 National Research Development Corporation Quinazoline derivatives, processes for their preparation, compositions containing them and their use as anti-cancer agents
GB8607683D0 (en) * 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
GB8707053D0 (en) * 1987-03-25 1987-04-29 Ici Plc Anti-tumour agents
US4857530A (en) * 1987-11-03 1989-08-15 Warner-Lambert Company Substituted quinazolinones as anticancer agents
GB8809978D0 (en) * 1988-04-27 1988-06-02 Ici Plc Anti-tumour agents
EP0365763A1 (en) * 1988-09-30 1990-05-02 Agouron Pharmaceuticals, Inc. Antiproliferative cyclic compounds
GB8829296D0 (en) * 1988-12-15 1989-01-25 Ici Plc Anti-tumour compounds

Also Published As

Publication number Publication date
GB2244708A (en) 1991-12-11
AU640016B2 (en) 1993-08-12
PT97799A (pt) 1992-02-28
GB9111656D0 (en) 1991-07-24
NZ238259A (en) 1993-07-27
JPH04235173A (ja) 1992-08-24
AU7707591A (en) 1991-12-05
IE64085B1 (en) 1995-07-12
IL98167A0 (en) 1992-06-21
FI912600A (fi) 1991-12-01
CA2042922A1 (en) 1991-12-01
GB2244708B (en) 1993-12-08
NO912071D0 (no) 1991-05-29
HUT57739A (en) 1991-12-30
EP0459730A3 (en) 1993-01-20
EP0459730A2 (en) 1991-12-04
CS160591A3 (en) 1992-01-15
US5280027A (en) 1994-01-18
ZA913730B (en) 1992-02-26
FI912600A0 (fi) 1991-05-30
IE911757A1 (en) 1991-12-04

Similar Documents

Publication Publication Date Title
NO912071L (no) Fremgangsmaater for fremstilling av anti-tumorforbindelser
CA2053253A1 (en) New aryl-and heteroarylethenylene derivatives and process for their preparation
AU9453098A (en) Imidazole derivatives and their use as farnesyl protein transferase inhibit ors
CA2037630A1 (en) Nitrogen-containing heterocylic compounds, their production and use
DK0799833T3 (da) Erythromycinderivater, fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler
EP0168262A3 (en) Pyrimidine derivatives, processes for preparation thereof and use thereof
HUT47110A (en) Process for producing pyrazolopyridine derivatives
DK9185A (da) Dihydropyridazinonderivater og fremgangsmaade til fremstilling deraf
NO874857D0 (no) Fremgangsmaate til fremstilling av rebeccamycin-analoger.
JPH0764815B2 (ja) 医薬用組成物に用いる化合物
RU2034846C1 (ru) СПОСОБ ПОЛУЧЕНИЯ СОЕДИНЕНИЙ ГРУППЫ ИМИДАЗО (1,2-b)-ПИРИДАЗИНА ИЛИ ИХ СОЛЕЙ
MXPA02006329A (es) 8-arilquinolinas sustituidas que son inhibidores de fosfodiesterasa-4.
WO2007007207A2 (en) Pharmaceutical compositions of 3, 5 -bis (arylidene) -4 -piperidones and analogues there of for modulating cell proliferation
CN117362323A (zh) 一类prmt5抑制剂及其用途
KR910007883A (ko) 퀴놀린 유도체, 그의 제조방법 및 용도
CA2042113A1 (en) Spiro-isoquinoline-pyrrolidines and analogs thereof useful as aldose reductase inhibitors
PT82897B (pt) Processo de preparacao de derivados de di-hidropiridazinona
CA2079733A1 (en) Hydrobromide of dc-89 derivative
US5128345A (en) Carcinostatic composition comprising indolquinolines
CA2364719A1 (en) 2-aminopyridines containing fused ring substituents
CN111377935A (zh) 选择性cdk4/6抑制剂及其应用
AU5453800A (en) Camptothecin beta-alanine esters with topoisomerase i inibhition
EP1638978B1 (en) 7-substituted camptothecin and camptothecin analogs and methods for preparing same
HUP0002335A2 (hu) 2,3-Dihidrofuro[3,2-b]piridin-származékok, eljárás a vegyületek előállítására és gyógyászati alkalmazásuk
AU1081200A (en) Novel pyrimidine derivatives and processes for the preparation thereof